The epidemic of heart failure with preserved ejection fraction may have an unexpected ally in the gut microbiome, offering new therapeutic targets beyond traditional cardiac interventions. This condition affects over half of all heart failure patients globally, with the cardiometabolic variant—linked to obesity, diabetes, and hypertension—representing the most prevalent form.
The research establishes that cardiometabolic disorders create a cascade of gut dysbiosis, depleting beneficial bacteria that produce short-chain fatty acids (SCFAs) including acetate, propionate, and butyrate. This microbial disruption compromises intestinal barrier function, triggering endotoxemia and activating inflammatory pathways through TLR4 and NLRP3 signaling. Simultaneously, protective gut metabolites decline while harmful compounds like TMAO increase, potentially accelerating myocardial fibrosis and diastolic dysfunction.
The therapeutic implications extend far beyond traditional cardiovascular medicine. SCFAs demonstrate multifaceted cardioprotective mechanisms: they provide alternative energy substrates to stressed heart muscle independent of standard metabolic pathways, enhance glucose and lipid metabolism through G protein-coupled receptor activation, and reduce blood pressure while dampening sympathetic nervous system activity. These compounds also function as epigenetic modulators and anti-inflammatory agents.
This gut-heart axis represents a paradigm shift in understanding heart failure pathogenesis. Unlike conventional approaches targeting cardiac symptoms, microbiome-directed interventions could address upstream causative factors. However, translating these mechanistic insights into clinical applications requires rigorous human trials to validate optimal SCFA delivery methods and dosing strategies. The integration of nutritional cardiology with microbiome science may ultimately reshape heart failure prevention and treatment protocols.